Coeptis Therapeutics (COEP)
Nasdaq-listed Coeptis developed cell therapy assets before its Z Squared merger.
$10.99
At close−1.03 (−8.57%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions45 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 12.70% | 6.73M shares | |
| Insiders9 holders · as of Feb 13, 2026 | 1.69% | 896.0K shares | |
| Otherremainder | ≈ 85.61% | 45.37M shares |
53.00M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (53.00M in the company's Sep 3, 2026 report, 3.51M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Mar 31, 2026
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Anchor Investment Management, LLC | 7.0K | 0.01% | 0 | May 1, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.